Cinque anni di utilizzo degli agenti stimolanti l’eritropoiesi nella terapia dell’anemia indotta da insufficienza renale nell’ASL di Pavia

摘要: Anemia is a frequent and highly debilitating condition associated with chronic kidney disease (CKD). Epoetin (alfa or beta) darbepoetin alfa are erythropoietin receptor agonists (ERAs) indicated for the treatment of anemia in patients CKD. Several studies demonstrated that ERAs effective CKD-related by increasing hemoglobin levels. To describe consumption costs trends Local Health Unit Pavia during period 2004–2008. We also calculated number treated ERAs, mean admnistration dose, cost per standard unit, dose conversion ratio (DCR) between epoetin patient alfa. Data this retrospective study were derived from administrative database Pavia. A sample was built selecting all who had diagnosis CKD received at least one ERA prescription 2004 2008. The evaluated annual pharmaceutical spending ERAs. analysed order to point out possible presence significant cost-drivers like patients, Received Daily Dose μg/IU. DCR their costs. increased systematically five-year (10% 12.7% annually, respectively). most important cost-driver explain increase spending. 179.10 IU: 1 μg. €1,334.57 €1,802.78 which explains growth Over period, cost-saving strategy compared